Journal of the American Society of Hypertension
Volume 1, Issue 4 , Pages 264-277 , July 2007

Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis

  • Matthew R. Weir, MD

      Affiliations

    • Division of Nephrology, University of Maryland School of Medicine, Baltimore, Maryland, USA
    • Dr. Matthew R. Weir has acted as an ad hoc consultant and participated in a speakers’ bureau for Novartis Pharmaceuticals Corporation.
    • Corresponding Author InformationCorresponding author: Matthew R. Weir, MD, Professor and Director, Division of Nephrology, University of Maryland School of Medicine, 22 South Greene Street, Room N3W143, Baltimore, Maryland 21201. Tel: 410-328-5720; fax: 410-328-5685.
    • ,
  • Christopher Bush, PhD

      Affiliations

    • Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
    • Drs. Christopher Bush, David R. Anderson, Jack Zhang, Deborah Keefe, and Andrew Satlin are employees of Novartis Pharmaceuticals Corporation and as such are eligible for Novartis stock and stock options.
    • ,
  • David R. Anderson, MD

      Affiliations

    • Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
    • Drs. Christopher Bush, David R. Anderson, Jack Zhang, Deborah Keefe, and Andrew Satlin are employees of Novartis Pharmaceuticals Corporation and as such are eligible for Novartis stock and stock options.
    • ,
  • Jack Zhang, MD, PhD

      Affiliations

    • Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
    • Drs. Christopher Bush, David R. Anderson, Jack Zhang, Deborah Keefe, and Andrew Satlin are employees of Novartis Pharmaceuticals Corporation and as such are eligible for Novartis stock and stock options.
    • ,
  • Deborah Keefe, MD

      Affiliations

    • Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
    • Drs. Christopher Bush, David R. Anderson, Jack Zhang, Deborah Keefe, and Andrew Satlin are employees of Novartis Pharmaceuticals Corporation and as such are eligible for Novartis stock and stock options.
    • ,
  • Andrew Satlin, MD

      Affiliations

    • Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
    • Drs. Christopher Bush, David R. Anderson, Jack Zhang, Deborah Keefe, and Andrew Satlin are employees of Novartis Pharmaceuticals Corporation and as such are eligible for Novartis stock and stock options.

References 

  1. Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren: where are we now, and where are we going?. J Hypertens. 2006;24:243–256
  2. Mooser V, Nussberger J, Juillerat L, Burnier M, Waeber B, Bidiville J, et al. Reactive hyper-reninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol. 1990;15:276–282
  3. Azizi M, Menard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation. 2004;109:2492–2499
  4. Lijnen P, Fagard R, Staessen J, Amery A. Effect of chronic diuretic treatment on the plasma renin-angiotensin-aldosterone system in essential hypertension. Br J Clin Pharmacol. 1981;12:387–392
  5. Skeggs LT, Kahn JR, Lentz K, Shumway NP. The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med. 1957;106:439–453
  6. Rongen GA, Lenders JW, Smits P, Thien T. Clinical pharmacokinetics and efficacy of renin inhibitors. Clin Pharmacokinet. 1995;29:6–14
  7. Wood JM, Maibaum J, Rahuel J, Grutter MG, Cohen NC, Rasetti V, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun. 2003;308:698–705
  8. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension. 2002;39:E1–E8
  9. Oh BH, Mitchell J, Herron J, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol. 2007;49:1157–1169
  10. Stanton A, Jensen C, Nussberger J, O’Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension. 2003;42:1137–1143
  11. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005;111:1012–1018
  12. Pool JL, Schmieder RE, Azizi M, Aldigier JC, Januszewicz A, Zidek W, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens. 2007;20:11–20
  13. American Heart Association Committee. American Heart Association committee report on blood pressure determination. Hypertension. 1988;11:210A–222A
  14. O’Brien E, Barton J, Nussberger J, Mulcahy D, Jensen C, Dicker P, et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension. 2007;49:276–284
  15. Thijs L, Den Hond E, Nawrot T, Staessen JA. Prevalence, pathophysiology and treatment of isolated systolic hypertension in the elderly. Expert Rev Cardiovasc Ther. 2004;2:761–769
  16. Dickerson LM, Gibson MV. Management of hypertension in older persons. Am Fam Physician. 2005;71:469–476
  17. Sica D. Optimizing hypertension and vascular health: focus on ethnicity. Clin Cornerstone. 2004;6:28–38
  18. Jamerson KA. Rationale for angiotensin II receptor blockers in patients with low-renin hypertension. Am J Kidney Dis. 2000;36:S24–S30
  19. Beaton SJ, Nag SS, Gunter MJ, Gleeson JM, Sajjan SS, Alexander CM. Adequacy of glycemic, lipid, and blood pressure management for patients with diabetes in a managed care setting. Diabetes Care. 2004;27:694–698
  20. Selby JV, Peng T, Karter AJ, Alexander M, Sidney S, Lian J, et al. High rates of co-occurrence of hypertension, elevated low-density lipoprotein cholesterol, and diabetes mellitus in a large managed care population. Am J Manag Care. 2004;10:163–170
  21. Messerli FH, Grossman E, Goldbourt U. Antihypertensive therapy in diabetic hypertensive patients. Am J Hypertens. 2001;14:12S–16S
  22. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393–404
  23. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–1252
  24. Law M, Morris JK, Jordan R, Wald N. Headaches and the treatment of blood pressure: results from a meta-analysis of 94 randomized placebo-controlled trials with 24,000 participants. Circulation. 2005;112:2301–2306
  25. Bourgault C, Senecal M, Brisson M, Marentette MA, Gregoire JP. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. J Hum Hypertens. 2005;19:607–613
  26. Cushman WC. The burden of uncontrolled hypertension: morbidity and mortality associated with disease progression. J Clin Hypertens (Greenwich). 2003;5:14–22

 This study was funded by Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.

PII: S1933-1711(07)00089-7

doi: 10.1016/j.jash.2007.04.004

Journal of the American Society of Hypertension
Volume 1, Issue 4 , Pages 264-277 , July 2007

Article Tools

* Image Usage & Resolution